Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Richwood Pharmaceutical Co. Inc.

Division of Takeda Pharmaceutical Co. Ltd.

Latest From Richwood Pharmaceutical Co. Inc.

Shire Shifts Upstream

Shire's latest acquisition, of Canada's BioChem Pharma, is its sixth in as many years, and the clearest sign yet of the shift which the UK-based specialty pharmaceutical company has to make towards earlier-stage research in order to keep up its impressive growth. Behind this growth is its low-risk Search & Development strategy: it seeks out promising, undervalued specialist-market drugs which it develops for new indications, or else finds new formulations for, after which it hands them on to its highly focused marketing and sales teams. A series of acquisitions-bolting on products, development programs and skills-has allowed Shire to quickly expand globally and broaden its portfolio. But as drugs get harder to find and more expensive, the company has had to throw its S&D net wider.
BioPharmaceutical Strategy

Medeva Changes Tack

Criticized for not properly managing growth, Medeva's managers contend they're building a sustainable business. They used profits from methylphenidate, an off-patent treatment for attention deficit disorder, to finance a long list of acquisitions, many of which didn't work out. When methylphenidate sales crashed with the entrance of generic competition, so did Medeva's credibility with investors. They're hoping their self-sustaining European and American infrastructure will help them attract the higher-risk, higher profit products they shunned in their original strategy but now need in order to dig themselves out of their profit hole.
BioPharmaceutical Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register